Seattle, WA, June 27, 2024 – RareCyte, Inc. (“RareCyte” or “the Company”) a Life Sciences company providing advanced Precision Biology platforms including instruments, reagents, software, and services announced today the completion of a $20M financing from new and existing investors.
Carlsbad, Calif. – April 9, 2024. Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications announces the launch of its new multiplex spatial biology assay services for rapid, whole-slide imaging and analysis of tissue sections at subcellular resolution. These assays utilize the Orion™ platform from RareCyte, Inc. and feature ready-to-run assay panels, as well as customization to serve studies across multiple drug targets and therapeutic areas.
Jan 22, 2024. Agenus Inc., a leader in developing immunological cancer treatments, today announced results from the NEST-1 study, an investigator-sponsored trial (IST) evaluating the combination of botensilimab and balstilimab (BOT/BAL).
January 18, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that RareCyte Inc., a precision biology company based in Seattle, Washington, is live on SOPHiA GENETICS. RareCyte has implemented the SOPHiA DDM™ Platform to complement its Precision Biology Services portfolio.
Seattle, WA, September 26th, 2023 - In the exciting, growing field of Spatial Biology, the Orion platform from RareCyte has emerged as the platform of choice across biomarker discovery, translational and clinical research.
CHICAGO, September 6, 2023 (giresearchfundation.com) – The American Cancer Society estimates there will be over 150,000 new cases of colorectal cancer diagnosed, making it one of the most diagnosed cancers in the United States. Over 52,000 Americans will die from the disease this year. Colorectal cancer can be successfully treated when caught early. Yet, advanced cases, especially where the cancer has spread are much more likely to be fatal.
TOKYO, June 29, 2023 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Mitsui Fudosan Co., Ltd. (TSE: 8801, President and CEO: Takashi Ueda, “Mitsui Fudosan”) announced today that Astellas will establish a “TME imaging and interactive research for innovation (TME iLab)” open innovation hub in October, 2023 in “MITSUI LINK-Lab KASHIWA-NO-HA 1” (Kashiwa City, Chiba Prefecture, “the Lab”) operated by Mitsui Fudosan.
Seattle, WA, November 14, 2022 – RareCyte, Inc., (“RareCyte” or “The Company”) a leading provider of Precision Biology products and services has been selected by Wellcome Leap to participate in the $50M In Utero program to create the scalable capacity to measure, model and predict gestational development, to achieve the goal of reducing global stillbirth rates by half. RareCyte will join world renowned researchers in pursuing this ambitious goal.
Chicago, IL, Nov 3rd, 2022 - Despite centuries of research, treating and curing cancer remains an urgent health research priority. With generous support from anonymous donors, the GastroIntestinal Research Foundation (GIRF) has launched a bold initiative, CA CURE, to identify and fund research to improve diagnostics and develop therapeutics focused on immunotherapies and personalized vaccines.
Seattle, WA, June 01, 2021 – RareCyte® announces a new biomarker liquid biopsy assay for the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer.
